Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 TherapyMaria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced MelanomaGeorgina V Long, James Larkin, Dirk Schadendorf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.Cell Reports. Medicine|December 9, 2020
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in MelanomaValsamo Anagnostou, Daniel C Bruhm, Noushin Niknafs, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 TrialSuzanne L Topalian, Shailender Bhatia, Asim Amin, et al.Pageof 11